全文获取类型
收费全文 | 3666篇 |
免费 | 229篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 37篇 |
妇产科学 | 16篇 |
基础医学 | 411篇 |
口腔科学 | 92篇 |
临床医学 | 386篇 |
内科学 | 851篇 |
皮肤病学 | 190篇 |
神经病学 | 327篇 |
特种医学 | 151篇 |
外国民族医学 | 1篇 |
外科学 | 597篇 |
综合类 | 34篇 |
一般理论 | 2篇 |
预防医学 | 243篇 |
眼科学 | 57篇 |
药学 | 175篇 |
中国医学 | 2篇 |
肿瘤学 | 314篇 |
出版年
2021年 | 78篇 |
2020年 | 41篇 |
2019年 | 59篇 |
2018年 | 83篇 |
2017年 | 63篇 |
2016年 | 74篇 |
2015年 | 69篇 |
2014年 | 77篇 |
2013年 | 138篇 |
2012年 | 166篇 |
2011年 | 206篇 |
2010年 | 100篇 |
2009年 | 93篇 |
2008年 | 159篇 |
2007年 | 178篇 |
2006年 | 207篇 |
2005年 | 154篇 |
2004年 | 175篇 |
2003年 | 174篇 |
2002年 | 152篇 |
2001年 | 131篇 |
2000年 | 135篇 |
1999年 | 114篇 |
1998年 | 46篇 |
1997年 | 27篇 |
1996年 | 23篇 |
1995年 | 24篇 |
1994年 | 19篇 |
1993年 | 18篇 |
1992年 | 60篇 |
1991年 | 67篇 |
1990年 | 52篇 |
1989年 | 52篇 |
1988年 | 41篇 |
1987年 | 51篇 |
1986年 | 44篇 |
1985年 | 42篇 |
1984年 | 36篇 |
1983年 | 29篇 |
1980年 | 14篇 |
1979年 | 20篇 |
1978年 | 20篇 |
1975年 | 15篇 |
1974年 | 20篇 |
1973年 | 29篇 |
1969年 | 16篇 |
1968年 | 18篇 |
1967年 | 14篇 |
1966年 | 16篇 |
1919年 | 16篇 |
排序方式: 共有3901条查询结果,搜索用时 265 毫秒
1.
2.
Bronwen J. Mayo Kate R. Secombe Anthony D. Wignall Emma Bateman Daniel Thorpe Claudio Pietra Dorothy M. Keefe Joanne M. Bowen 《Cancer chemotherapy and pharmacology》2020,85(4):793-803
Lapatinib is a small molecule tyrosine kinase inhibitor used to treat breast cancer, often in combination with chemotherapy. Diarrhoea commonly occurs in up to 78% of patients undertaking lapatinib treatment. The mechanism of this diarrhoea is currently unknown. Elsiglutide is a GLP-2 analogue known to increase cell proliferation and reduce apoptosis in the intestine. We used a previously developed rat model of lapatinib-induced diarrhoea to determine if co-treatment with elsiglutide was able to reduce diarrhoea caused by lapatinib. Additionally, we analysed the caecal microbiome of these rats to assess changes in the microbiome due to lapatinib. Rats treated with lapatinib and elsiglutide had less severe diarrhoea than rats treated with lapatinib alone. Serum lapatinib levels, blood biochemistry, myeloperoxidase levels and serum limulus amebocyte lysate levels were not significantly different between groups. Rats treated with lapatinib alone had significantly higher histopathological damage in the ileum than vehicle controls. This increase was not seen in rats also receiving elsiglutide. Rats receiving lapatinib alone had lower microbial diversity than rats who also received elsiglutide. Elsiglutide was able to reduce diarrhoea from lapatinib treatment. This does not appear to be via reduction in inflammation or barrier permeability, and may be due to thickening of mucosa, leading to increased surface area for fluid absorption in the distal small intestine. Microbial changes seen in this study require further research to fully elucidate their role in the development of diarrhoea. 相似文献
3.
Sameer Arora Kamal Shemisa Muthiah Vaduganathan Arman Qamar Ankur Gupta Sushil K. Garg Dharam J. Kumbhani Helen Mayo Houman Khalili Ambarish Pandey Sandeep R. Das 《Journal of the American College of Cardiology》2019,73(19):2454-2464
Ticagrelor is a cornerstone of modern antithrombotic therapy alongside aspirin in patients with acute coronary syndrome and after percutaneous coronary intervention. Adverse effects such as bleeding and dyspnea have been associated with premature ticagrelor discontinuation, which may limit any potential advantage of ticagrelor over clopidogrel. The randomized trials of ticagrelor captured adverse events, offering the opportunity to more precisely quantify these effects across studies. Therefore, a meta-analysis of 4 randomized clinical trials of ticagrelor conducted between January 2007 and June 2017 was performed to quantify the incidence and causes of premature ticagrelor discontinuation. Among 66,870 patients followed for a median 18 months, premature ticagrelor discontinuation was seen in 25%; bleeding was the most common cause of discontinuation followed by dyspnea. Versus the comparators, the relative risk of dyspnea-related discontinuation during follow-up was 6.4-fold higher, the relative risk of bleeding was 3.2-fold higher, and the relative risk of discontinuation due to any adverse event was 59% higher for patients receiving ticagrelor. Understanding these potential barriers to adherence to ticagrelor is crucial for informed patient-physician decision making and can inform future efforts to improve ticagrelor adherence. This review discusses the incidence, causes, and biological mechanisms of ticagrelor-related adverse effects and offers strategies to improve adherence to ticagrelor. 相似文献
4.
5.
Yushi Katsuyama Norihisa Taira Tatsuya Tsuboi Masato Yoshioka Yuri Okano Hitoshi Masaki 《Experimental dermatology》2019,28(Z1):64-68
Skin sensitivity is a serious problem for many people, and it can be induced by various factors such as UV irradiation, physical and mental stresses, air pollution, dry air and so on. Skin dryness triggered by UV and dry air is one of the most important causes inducing the development of sensitive skin, and it has been reported that oxidative stress contributes to skin dryness. In this study, we investigated whether treatment with 3‐O‐laurylglyceryl ascorbate (VC‐3LG), which is an amphipathic ascorbic acid derivative, can suppress the development of sensitive skin. The results demonstrate that VC‐3LG restores the expression levels of interleukin‐1α, nerve growth factor and matrix metalloprotease‐9 in the dry skin models of reconstructed human epidermal equivalents (RHEEs) and in H2O2‐treated keratinocytes. In addition, VC‐3LG suppresses the dendrite elongation of nerve cells induced in RHEEs by dry skin conditions and by H2O2 treatment of keratinocytes. Therefore, we consider that treatment of the skin with VC‐3LG is an effective approach to improve the development of sensitive skin. 相似文献
6.
7.
8.
9.
10.